Giant Cell Tumor

Slide 1 · Giant Cell Tumor of Bone

Pathogenesis • Morphology • Clinicopathologic reasoning

Bone neoplasm with locally destructive behavior

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Identify the neoplastic population within this giant cell–rich lesion.

Explain the RANKL-dependent recruitment of osteoclasts and resulting bone loss.

Connect epiphyseal location, gross and microscopic findings with symptoms.

Interpret recurrence, lung involvement, and the role of RANKL inhibition.

Slide 3 · Three cellular populations define the tumor

Stromal tumor cells

Mononuclear neoplastic population

Macrophages

Additional mononuclear cells

Osteoclast-type giant cells

Abundant recruited nonneoplastic cells

Slide 4 · Benign classification versus destructive behavior

Biologic designation

Clinically consequential behavior

The tumor is described as benign.

Stromal cells comprise its neoplastic component.

Typical tumor cells are comparatively uniform.

Osteoclast-mediated resorption can be extensive.

The cortex may be destroyed by expansion.

Local recurrence and pathologic fracture are important.

Slide 5 · Typical patient population

The tumor is uncommon in the overall bone-tumor spectrum.

Presentation mainly in the third to fifth decades.

The bone-tumor summary table lists a characteristic range of 20–40 years.

Age supports the diagnostic context; It does not independently establish the diagnosis.

Slide 6 · Epiphyseal origin is a core anatomic clue

Primary origin is typically within the epiphysis of a long bone.

Tumor growth may extend from the epiphysis into the metaphysis.

The close relation to a joint helps explain arthritis-like complaints.

The anatomic pattern should be integrated with morphology.

Slide 7 · Epiphysis, metaphysis, and the expanding tumor

Epiphysis

Metaphysis

Shaft

Origin

Typically epiphyseal

Extension

May reach the metaphysis

Pattern

Often near an articular surface

Slide 8 · Periarticular predilection: Near the knee

The distal femur and proximal tibia are the most frequent sites.

These positions place the lesion close to the knee joint.

The tumor does not have to originate from synovium to produce joint-like symptoms.

Almost any skeletal bone may nonetheless be affected.

Slide 9 · Neoplastic cells versus recruited cells

Primitive osteoblast-precursor stroma

Osteoclast lineage

Represents the neoplastic population.

Contains acquired H3-3A mutations.

Expresses increased RANKL.

Comprises nonneoplastic cells and precursors.

Responds to stromal RANKL signals.

Produces the bone-resorbing phenotype.

Slide 10 · The giant cells are not the transformed population

Most cells in the lesion are nonneoplastic osteoclasts or their precursors.

The tumor is driven by a smaller neoplastic stromal compartment.

Giant-cell abundance reflects cellular recruitment and differentiation.

The most visually conspicuous cell may not be the initiating neoplastic cell.

Slide 11 · Normal bone remodeling uses RANK–RANKL signaling

Osteoblast / stroma

RANKL on cell surface

Osteoclast precursor

RANK receives signal

Mature osteoclast

Physiologic resorption

Normal remodeling: Signaling remains under feedback control.

Slide 12 · RANKL connects osteoblast lineage to osteoclasts

RANK is expressed by osteoclast precursor cells.

RANKL is normally expressed by osteoblasts and marrow stromal cells.

RANKL-induced RANK signaling activates NF-κB.

This signaling is necessary for osteoclast generation and survival.

Normal physiology provides the mechanism exploited by the neoplasm.

Slide 13 · A normal cellular sequence produces osteoclasts

Stromal signal

RANKL available to target cells

Receptor engagement

RANK on osteoclast precursors

Differentiation

Functional osteoclasts develop

Resorption

Controlled bone turnover

In normal bone, formation and resorption are locally coupled.

Slide 14 · Osteoprotegerin restrains RANKL signaling

OPG is a soluble decoy receptor made by osteoblasts and other cells.

OPG binds RANKL and prevents its binding to RANK.

It consequently limits differentiation of osteoclasts.

The RANKL–OPG balance participates in physiologic skeletal remodeling.

OPG is a regulator in normal remodeling; Robbins does not specify an OPG mutation in GCT.

Slide 15 · Normal feedback compared with giant cell tumor

Remodeling under normal control

Giant cell tumor microenvironment

Resorption is linked to new bone formation.

Osteoblast–osteoclast signaling is regulated.

RANKL is opposed by decoy-receptor activity.

Neoplastic stroma expresses high RANKL.

Osteoclast lineage is strongly recruited.

Localized resorption becomes destructive.

Slide 16 · M-CSF is part of the normal osteoclast program

Macrophage colony-stimulating factor is produced by osteoblasts.

M-CSF is crucial for osteoclast generation in normal remodeling.

RANKL and M-CSF therefore act within a broader differentiation network.

For GCT specifically, increased tumor-derived RANKL.

Additional remodeling pathway shown as parent context—not a claim of GCT-specific mutation.

Slide 17 · High tumor-derived RANKL creates a destructive circuit

Mutant neoplastic stroma

High RANKL expression

Osteoclast precursor

Differentiation stimulated

Osteoclast giant cell

Destructive resorption

Tumor-associated signaling: Increased osteoclast formation drives osteolysis.

Slide 18 · Osteolysis follows a tumor–host cell interaction

Neoplastic stroma

Excess RANKL expressed

Osteoclast recruitment

Precursors expand and mature

Bone resorption

Trabeculae are lost

Structural failure

Cortex and bone integrity weaken

The tissue damage results substantially from recruited, nonneoplastic cells.

Slide 19 · H3-3A mutation identifies a genetic driver

The neoplastic stromal cells harbor acquired H3-3A mutations.

H3-3A encodes histone H3.3, a chromatin packaging protein.

The mutation supports a neoplastic rather than purely reactive origin.

Robbins does not specify how this mutation initiates tumor development.

Slide 20 · Established molecular facts versus unknown mechanism

Established in the source

Not resolved

H3-3A is mutated in the tumor cells.

Histone H3.3 participates in chromatin packaging.

Neoplastic stromal cells express high RANKL.

The precise route from the mutation to tumor formation.

A single fully mapped downstream oncogenic cascade.

A stated H3-3A alteration in all giant cells.

Slide 21 · Cellular and molecular attribution

Population

Neoplastic?

Main teaching implication

Stromal osteoblast precursors

Yes

H3-3A mutations; High RANKL

Osteoclast precursors

No

Recruited and differentiate

Osteoclast-type giant cells

No

Resorption and conspicuous morphology

Macrophages

Not identified as tumor cells

Component of mixed cell population

Slide 22 · Why bone is resorbed rather than replaced

Excess RANKL stimulates formation and persistence of osteoclasts.

The recruited giant-cell lineage is capable of destroying mineralized bone.

The normal coupling of resorption and formation is disrupted.

The resulting defect can expand despite benign tumor classification.

Slide 23 · One biological mechanism explains multiple findings

RANKL excess

Pathologic osteoclast signaling

Extensive resorption

Expansile osteolytic defect

Cortical loss

Outward extension of mass

Biomechanical risk

Fracture and joint-like pain

Slide 24 · Anatomic spread from epiphysis toward metaphysis

Epiphysis

Metaphysis

Shaft

Early response

Localized bone resorption

Progression

Thinning or cortical destruction

Late consequence

Fracture or soft-tissue bulge

Slide 25 · Most cases involve the distal femur or proximal tibia

The tumor commonly develops on either side of the knee.

The epiphyseal origin is more discriminating than the bone name alone.

Extension into the metaphysis does not negate epiphyseal origin.

The presentation is compatible with a primarily osseous lesion.

Slide 26 · Anatomic distribution is characteristic, not exclusive

Virtually any bone can be involved.

An atypical location should prompt more careful clinicopathologic correlation.

Location is a pattern-recognition clue, not a substitute for tissue diagnosis.

Local destructive behavior remains relevant outside the knee.

Slide 27 · Local symptoms emerge from lesion location

Near a joint

Through weight-bearing bone

Periarticular lesion may mimic arthritis.

Pain and functional limitation may dominate.

A bone lesion should remain in the differential.

Resorption reduces skeletal strength.

Tumor may destroy supporting cortex.

Pathologic fracture may be the presenting complication.

Slide 28 · From microscopic signaling to pathologic fracture

Stromal RANKL

Stimulates osteoclast differentiation

Osteoclasts

Resorb supporting bone

Cortex

Thins and may be breached

Fracture

Weak bone fails under load

Slide 29 · Imaging pattern: Lytic and expansile lesion

Robbins Fig. 26.25 describes a predominantly lytic, expansile bone tumor.

Cortical destruction was evident in the illustrated proximal fibular lesion.

The same example included a pathologic fracture.

The radiologic pattern coheres with vigorous osteoclast-mediated bone resorption.

Source figure described; Textbook image not reproduced.

Slide 30 · Correlating radiologic and gross observations

Observation

Pathologic explanation

Predominantly lytic defect

Destruction of mineralized bone by osteoclasts

Expansile contour

Growth enlarges the intraosseous lesion

Cortical interruption

Overlying cortex is destroyed

Reactive thin shell

Bone reaction may delineate the mass

Associated fracture

Mechanical integrity is diminished

Slide 31 · From cortical destruction to a reactive bone shell

Schematic cross-section

Bone resorption

Tumor expands in cancellous bone

Cortical injury

Overlying cortex can be destroyed

Reactive shell

Thin bone may outline soft-tissue bulge

Slide 32 · Destruction can produce an extraosseous bulge

The overlying cortex may be eroded or fully destroyed.

A bulky lesion may protrude toward adjacent soft tissue.

Thin reactive bone can delineate the tumor margin.

A reactive shell does not imply that the underlying lesion is biologically harmless.

Slide 33 · Pathologic fracture is a direct structural complication

Osteolysis removes normal load-bearing architecture.

Cortical damage reduces resistance to mechanical stress.

Fracture may occur through the weakened tumor-bearing bone.

In this setting, fracture signifies impaired mechanical integrity rather than necessarily malignant transformation.

Slide 34 · Gross morphology: Red-brown expansile mass

The lesion can form a large, red-brown tissue mass.

Bone destruction may permit visible bulging beyond the native contour.

Gross coloration and expansion must be interpreted with microscopy.

The appearance is consistent with a vascular and osteoclast-rich lesion, but color is not diagnostic.

Slide 35 · Cystic degeneration modifies the gross pattern

Giant cell tumors frequently show cystic degenerative changes.

Gross heterogeneity therefore does not exclude this diagnosis.

Correlation with the cellular tumor regions is needed.

Distinguish degenerative cyst formation from a separately defined aneurysmal bone cyst.

Slide 36 · Gross and microscopic findings are concordant

Red-brown mass

Visible bulky lesion

Cell-rich tumor

Mononuclear cells plus giant cells

Osteoclast activity

Excessive bone resorption

Expansile defect

Cortical disruption and cystic change

Slide 37 · Core histologic pattern: Uniform stroma and giant cells

The mononuclear stromal tumor cells are relatively uniform and oval.

Numerous osteoclast-type giant cells are interspersed.

Macrophages contribute to the mixed cellular population.

The key is to recognize which component is neoplastic.

Slide 38 · Mononuclear cells: The neoplastic compartment

The stromal cells have primitive osteoblast-precursor identity.

They are described as uniform and oval in textbook sections.

Their chromatin-associated mutation is H3-3A.

The stromal compartment drives recruitment of osteoclast-lineage cells.

Slide 39 · Giant cells can contain exceptionally many nuclei

The giant cells are of osteoclast type, not malignant epithelial syncytia.

Giant cells containing 100 or more nuclei.

The multinucleated cells form a conspicuous component of the lesion.

The large number of nuclei is not itself a criterion of malignancy.

Slide 40 · Schematic microscopic architecture of giant cell tumor

Schematic illustration — not an H&E section

Small oval cells

Neoplastic stroma

Large giant cells

Osteoclast type

Slide 41 · Mitoses and necrosis require contextual interpretation

Mitotic activity may be prominent in giant cell tumor.

Areas of necrosis may also be encountered.

Neither finding negates the overall diagnosis when the other classic features align.

The lesion can remain locally aggressive despite its usual benign classification.

Slide 42 · Bland cellular appearance is compatible with aggression

Cytology

Behavior

Mononuclear population is described as uniform.

Multinucleated giant cells may be numerous.

Mitoses and necrosis can be present.

RANKL-mediated osteolysis is highly destructive.

Local recurrence is common after curettage.

Rare pulmonary metastasis is reported.

Slide 43 · Correct cellular attribution prevents a conceptual error

The giant-cell-rich field does not mean giant cells are tumor initiators.

The stromal cells are the genetically altered population.

Giant-cell recruitment arises from tumor–host paracrine signaling.

Clinical consequences can exceed the apparent cytologic atypia.

Slide 44 · A pattern-based clinicopathologic approach

Domain

Feature favoring giant cell tumor

Patient context

Most often third–fifth decades

Anatomic setting

Epiphyseal long-bone lesion, often around knee

Radiology / gross

Expansile osteolysis and cortical destruction

Microscopy

Uniform oval stroma plus osteoclast giant cells

Pathogenesis

H3-3A-mutant stroma expressing high RANKL

Slide 45 · Location patterns help narrow bone-tumor diagnosis

Entity

Typical skeletal location

Usual age table

Giant cell tumor

Epiphysis of long bones

20–40 years

Nonossifying fibroma

Eccentric metaphysis around knee

Children / adolescents

Ewing sarcoma

Diaphysis of long bones

10–20 years

Chondroblastoma

Epiphysis of long bones

10–20 years

Slide 46 · Distinguish aneurysmal bone cyst from giant cell tumor

Characteristic

Giant cell tumor

Aneurysmal bone cyst

Defining pattern

Mononuclear stroma and giant cells

Multiple blood-filled spaces

Typical age

Third–fifth decades

Frequently adolescents

Molecular basis

H3-3A mutation in stromal cells

USP6 rearrangement in neoplastic cells

Growth

Epiphyseal osteolysis

Expansile lytic lesion; Cystic architecture

Slide 47 · Distinguish nonossifying fibroma from giant cell tumor

Characteristic

Giant cell tumor

Nonossifying fibroma

Predilection

Epiphysis of long bone

Eccentric metaphysis

Typical population

Adults

Children / adolescents

Biology

H3-3A; High RANKL

RAS-pathway mutations described

Presentation

Pain / fracture possible

Often incidental, asymptomatic

Slide 48 · Giant cell tumor contrasted with osteosarcoma

Characteristic

Giant cell tumor

Osteosarcoma

Classification

Benign, locally aggressive

Malignant osteoid-forming tumor

Common location

Epiphysis

Metaphysis around knee

Microscopic focus

Stroma with osteoclast giant cells

Malignant cells producing osteoid

Main mechanism

Tumor-induced bone resorption

Neoplastic bone/osteoid production

Slide 49 · Giant cell tumor contrasted with Ewing sarcoma

Characteristic

Giant cell tumor

Ewing sarcoma

Typical age

Third–fifth decades

Usually younger than 20 years

Typical region

Epiphysis

Diaphysis of long bones

Cytology

Mononuclear cells and giant cells

Primitive small round cells

Molecular context

H3-3A-mutant stroma

EWSR1 family gene fusions

Slide 50 · Giant cell-rich histology needs context

Misleading shortcut

More reliable evaluation

“Giant cells = giant cell tumor”

Giant cells occur in other bone lesions

“No atypia = no clinical risk”

Examine extent of osteolysis and fracture

“Epiphyseal = single possible entity”

Age and distinct stromal morphology matter

“Recurrence = sarcoma”

Local recurrence occurs in benign aggressive GCT

Slide 51 · Curettage addresses the local tumor burden

Curettage as a treatment approach.

Curettage is a local surgical technique rather than systemic therapy.

However, recurrent tumor after local intervention is common.

The operative decision must account for local structural damage and morbidity.

Slide 52 · Local recurrence is a major outcome

Local recurrence in approximately 40%–60% of cases following curettage.

This textbook figure is historical/source-specific; No treatment modification is stated.

Recurrence reflects the recognized locally aggressive natural history.

Long-term clinical monitoring is important in the lecture’s risk framework.

Slide 53 · Local recurrence and malignancy are different concepts

Local recurrence

Malignancy

Tumor reappears at the original skeletal site.

Can follow curettage.

Reported frequently in the Robbins account.

Requires separate diagnostic reasoning.

Cannot be inferred from recurrence alone.

Benign GCT may nonetheless behave aggressively.

Slide 54 · Pulmonary metastases are uncommon but possible

Lung metastasis in up to 4% of giant cell tumors.

This is an exception to the lesion’s usual benign designation.

The text describes a generally favorable course for these pulmonary lesions.

The percentage refers to the textbook account, not a risk estimate for an individual patient.

Slide 55 · Pulmonary deposits may have an unusually favorable course

Some lung metastases may regress spontaneously.

Other metastatic pulmonary nodules may be cured by excision.

This course differs from the expected behavior of many high-grade sarcomas.

Clinical behavior should not be inferred from the word “metastasis” alone.

Slide 56 · Denosumab interrupts the osteoclastogenic circuit

Neoplastic stroma

Produces excess RANKL

Targeted inhibition

Denosumab binds RANKL

Blocked RANK input

Reduces osteoclast differentiation

Biologic consequence

Interrupts tumor-linked bone resorption

This is the mechanism-based rationale.

Slide 57 · Therapeutic rationale follows the RANKL mechanism

Denosumab is an inhibitor of RANKL signaling.

It targets the pathway mediating osteoclast recruitment and activity.

It as an alternative when resection could carry major morbidity.

The textbook excerpt does not supply a dosing schedule or contemporary treatment algorithm.

Slide 58 · Treatment choice depends on local clinical context

Local intervention

RANKL pathway intervention

Curettage is an established treatment approach.

Local recurrence is an important limitation.

Anatomic consequences of bone removal matter.

Denosumab has a mechanism-based rationale.

Potentially relevant when surgery is morbid.

Not a substitute for individual multidisciplinary planning.

Slide 59 · Build the clinical diagnosis from concordant domains

Site and age identify a characteristic bone-tumor scenario.

Imaging and gross findings disclose the destructive pattern.

The mixed mononuclear and giant-cell populations provide histologic context.

Tumor-derived RANKL and H3-3A connect cellular biology with the phenotype.

Slide 60 · Case 1 — periarticular pain in an adult

Teaching vignette (hypothetical)

A 34-year-old has progressive pain near the knee.

Imaging demonstrates an expansile, predominantly lytic epiphyseal lesion.

Tissue shows uniform oval stromal cells and osteoclast-type giant cells.

Which cellular population is neoplastic, and what explains the osteolysis?

Slide 61 · Case 1 — mechanism-based interpretation

The mononuclear stromal population is neoplastic.

High RANKL expression promotes osteoclast precursor differentiation.

The large osteoclast-type giant cells are recruited, nonneoplastic cells.

The same process links histology to destructive imaging and pain.

Slide 62 · Case 2 — fracture through a bone tumor

Teaching vignette (hypothetical)

A long-bone lesion expands from the epiphysis toward the metaphysis.

The cortex is thinned and partially destroyed.

A fracture occurs through the involved segment.

Explain the fracture without assuming the lesion is a high-grade sarcoma.

Slide 63 · Case 2 — structural rather than cytologic explanation

The RANKL–osteoclast axis removes the bone needed for load bearing.

Expansion and cortical destruction reduce structural integrity.

Pathologic fracture is therefore biologically plausible for benign GCT.

Local aggressiveness and malignant classification are not synonyms.

Slide 64 · Case 3 — a giant-cell-rich biopsy

Teaching vignette (hypothetical)

A bone-biopsy section contains many multinucleated osteoclast-type cells.

A less conspicuous population of mononuclear stromal cells surrounds them.

The clinical impression is of an epiphyseal bone tumor.

What is the most important pitfall when interpreting the biopsy?

Slide 65 · Case 3 — avoid a giant-cell counting diagnosis

Many giant cells do not by themselves define the lesion.

Assess the mononuclear population and the skeletal location.

Other giant-cell-containing lesions occur in the neighboring differential.

A correct explanation identifies the cell responsible for tumor biology.

Slide 66 · Integrated disease model: Four linked domains

Mutation

H3-3A in stromal cells

Signaling

High RANKL production

Cellular response

Nonneoplastic giant cells

Outcome

Osteolysis and fracture risk

Mutation-to-tumor initiation remains mechanistically incompletely defined.

Slide 67 · Five anchor findings to retain

Finding

Interpretive value

Epiphyseal lesion near knee

Characteristic clinical topography

Uniform stromal cells

Neoplastic cell population

Many osteoclast-like giant cells

Recruited cellular effectors

High RANKL; H3-3A mutation

Mechanistic and genetic context

Recurrence; Rare lung spread

Benign designation does not erase clinical risk

Slide 68 · Final clinicopathologic synthesis

Giant cell tumor of bone is a stromal neoplasm with abundant reactive osteoclasts.

H3-3A-mutant, RANKL-expressing cells drive local osteoclast-mediated destruction.

The typical lesion is an epiphyseal, expansile osteolytic bone tumor.

Major clinical issues are fracture, local recurrence, and rare lung involvement.

Slide 69 · Primary reference and source boundaries

Primary textbook

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th ed. 2026.

Giant Cell Tumor section: bone neoplasms.

Context used selectively:

Bone remodeling; bone-tumor comparison table; adjacent aneurysmal bone cyst and nonossifying fibroma sections.